Psychedelic-assisted psychotherapy and its potential to manage demoralization: A brief exploration of an alternative approach to end of life care
May 7, 2025 DOI: 10.70462/acim.2025.1.001 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Psychotherapist End-of-life care |
| Key findings | Australia is the first country to approve MDMA and psilocybin for clinical treatment of PTSD and treatment-resistant depression. |
Abstract
Australia has become the first country to approve the use of psychedelics, namely MDMA and psilocybin, for clinical treatment of post-traumatic stress disorder and treatment-resistant depression. Here, we briefly explore the history of its use, how it works, and the hope it may provide people receiving end-of-life care.